Core Insights - Kiniksa Pharmaceuticals is focusing on expanding the adoption of ARCALYST for recurrent pericarditis, with plans for physician education and marketing initiatives to support earlier use in the disease course [1][4] - The company has set a net revenue guidance of $900 million to $920 million for 2026, despite facing seasonal headwinds in the specialty drug sector [2] - ARCALYST product revenue saw a significant increase of 65% year-over-year to $202.1 million in Q4 2025, contributing to a full-year revenue of $677.6 million, marking the highest year-on-year growth to date [3][14] Commercial Performance - The number of prescribers for ARCALYST exceeded 4,150 by the end of 2025, with approximately 29% prescribing it for two or more recurrent pericarditis patients [4] - Market penetration for the two-plus recurrence target market rose to about 18% by the end of 2025, up from 15% mid-year and 13% at the end of 2024 [5] - Approximately 20% of ARCALYST prescriptions are now written after a first recurrence, indicating a shift towards earlier treatment [6] Pipeline Developments - Kiniksa initiated a phase II/III clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with phase II data expected in the second half of 2026 [7][8] - KPL-387 aims to enhance market penetration through monthly dosing with an auto-injector, with 75% of recurrent pericarditis patients preferring its target product profile [11] - KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, is expected to enter clinical trials by the end of 2026 [12] Financial Overview - Kiniksa reported a net income of $14.2 million in Q4 2025, a turnaround from a net loss of $8.9 million in the prior-year quarter, with a full-year net income of $59.0 million compared to a net loss of $43.2 million in 2024 [14] - Operating expenses increased due to higher costs associated with ARCALYST growth and investments in commercialization [13] - The company ended 2025 with $414.1 million in cash, indicating strong liquidity and a positive cash flow outlook [15]